Mylan launches generic Avodart capsules
CANONSBURG — Mylan N.V. said Friday it has launched Dutasteride capsules, the 0.5 mg. generic version of GlaxoSmithKline’s Avodart capsules.
Mylan, which received final approval from the U.S. Food and Drug Administration for the U.S. launch of the product, which is indicated as monotherapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery.
The medicine may also be used with tamsulosin for the treatment of symptomatic BPH in men with an enlarged prostate.
Dutasteride capsules had U.S. sales of approximately $297.2 million for the 12 months ending April 30, according to IMS Health.